Patenting stem cells: filing date is the key

In the inaugural issue of the LSIPR quarterly, Andy Sanderson analysed options of obtaining patent protection in the aftermath of the Brüstledecision of the Court of Justice of the European Union (CJEU) that further restricted options of applicants to obtain patent protection for human embryonic stem (hES) cell-related inventions.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

UPC bans Meril Life Sciences from selling infringing heart valve

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

White & Case hires experienced litigator from A&O Shearman

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Patenting stem cells: filing date is the key

Editor's picks

Editor's picks

More features